Evercore ISI Group Maintains Outperform on Cerence, Raises Price Target to $150

Evercore ISI Group analyst Chris McNally maintains Cerence (NASDAQ:CRNC) with a Outperform and raises the price target from $125 to $150.

Evercore ISI Group analyst Chris McNally maintains Cerence (NASDAQ:CRNC) with a Outperform and raises the price target from $125 to $150.

Total
0
Shares
Related Posts
Read More

Regeneron Pharmaceuticals Announced Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH 2022

- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new and updated data from a Phase 1 and pivotal Phase 2 trial (ELM-1 and ELM-2) evaluating investigational odronextamab in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

REGN